In several countries, PSMA-ligands show to be a valuable treatment option in patients with metastasized, castration-resistant prostate cancer, so that several trials such as the “VISION” trial (NCT03511664) are on their way. This evidence concerns the gene FOLH1 and Familial prostate cancer.